All In Biotech

NDA 018741 · Organon

Diprolene

Betamethasone Dipropionate · Topical

Last checked: Nov 19, 2026Latest source record: May 1, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

Jul 27, 1983

Approved uses

2

Original approval plus efficacy supplements

Registered trials

127

30 Phase 3, 11 recruiting

FAERS reports

6,488

4,390 serious, 547 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 19, 2025.

DIPROLENE ® Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. DIPROLENE Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older. ( 1 )

Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of DIPROLENE Ointment in corticosteroid responsive dermatoses is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 28, 2006 Supplement 28 · Efficacy LetterLabel
  • Jul 27, 1983 Original approval · Type 3 - New Dosage Form
1 products under this application
  • DIPROLENE · BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · OINTMENT, AUGMENTED, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,469
  • off label use666
  • macular degeneration533
  • nausea527
  • psoriasis508
  • pruritus474
  • pain472
  • condition aggravated426
  • fatigue410
  • pain in extremity409
  • rash404
  • headache402

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200423
200542
200634
200738
200827
200938
201026
201152
201272
201354
201467
2015122
2016201
2017230
2018287
2019389
2020471
2021779
2022786
2023791
2024638
2025747
2026574

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diprolene (Betamethasone/Propylene Glyc)

2024 spending

$13K

Beneficiaries

30

64 claims

Per beneficiary

$430

$4.08 per unit

View as table
YearSpending
2020$0
2021$0
2022$11,451
2023$12,001
2024$12,886

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 226 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.